Apart from ibrutinib, individuals with M-CLL, devoid of TP53 aberrations and healthy more than enough to tolerate FCR therapy, may still be great candidates for your latter, Along with the advantage currently being that this treatment method is often done in six months when ibrutinib have to be taken indefinitely. This option might be especially im